Elutia (ELUT) Income from Discontinued Operations (2022 - 2026)
Elutia's (ELUT) quarterly Income from Discontinued Operations came in at $425000.0 in Q1 2026, up 120.77% year-over-year from $192506.1 in Q1 2025, and down 99.45% quarter-over-quarter from $77.3 million in Q4 2025.
Analysis
Elutia (ELUT) Income from Discontinued Operations (2022 - 2026) Analysis & Trends
Elutia has disclosed Income from Discontinued Operations across 5 years of filings, most recently posting $425000.0 for Q1 2026.
- In Q1 2026, Income from Discontinued Operations rose 120.77% year-over-year to $425000.0; the TTM figure through Jun 2026 stood at $74.2 million (up 970.96% YoY), while the FY2025 annual figure was $69.3 million, up 904.87% from the prior year.
- Income from Discontinued Operations came in at $425000.0 for Q1 2026 at Elutia, down from $77.3 million in the prior quarter.
- In the past five years, Income from Discontinued Operations ranged from a high of $77.3 million in Q4 2025 to a low of -$3.5 million in Q3 2025.
- Average Income from Discontinued Operations over 5 years is $5.1 million, with a median of -$524000.0 recorded in 2023.
- The largest YoY upside for Income from Discontinued Operations was 4155.67% in 2025 against a maximum downside of 1499.44% in 2025.
- Over 5 years, Income from Discontinued Operations stood at $575000.0 in 2022, then surged by 927.48% to $5.9 million in 2023, then slumped by 132.26% to -$1.9 million in 2024, then jumped by 4155.67% to $77.3 million in 2025, then slumped by 99.45% to $425000.0 in 2026.
- Per Business Quant data, the three most recent Income from Discontinued Operations figures were $425000.0 in Q1 2026, $77.3 million in Q4 2025, and -$3.5 million in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Discontinued) (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 181.23 Bn | 175.63 Bn | 7.27 Bn | - |
| 2 | Intuitive Surgical | 127.53 Bn | 122.31 Bn | 1.96 Bn | - |
| 3 | Medtronic | 117.08 Bn | 108.26 Bn | 6.34 Bn | - |
| 4 | Stryker | 105.08 Bn | 101.60 Bn | 4.50 Bn | - |
| 5 | Boston Scientific | 64.51 Bn | 63.97 Bn | 3.85 Bn | - |
| 6 | Edwards Lifesciences | 49.91 Bn | 45.66 Bn | 1.35 Bn | - |
| 7 | Alcon | 33.07 Bn | 31.61 Bn | 1.68 Bn | - |
| 8 | Dexcom | 32.35 Bn | 30.40 Bn | 830.00 Mn | - |
| 9 | Steris | 20.78 Bn | 20.30 Bn | 684.20 Mn | - |
| 10 | Elutia | 37.26 Mn | 17.36 Mn | 1.45 Mn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Mar 31, 2026 | 425,000.00 |
| Dec 31, 2025 | 77.30 Mn |
| Sep 30, 2025 | -3.49 Mn |
| Jun 30, 2025 | -2.52 Mn |
| Mar 31, 2025 | -2.05 Mn |
| Dec 31, 2024 | -1.91 Mn |
| Sep 30, 2024 | -2.05 Mn |
| Jun 30, 2024 | 180,000.00 |
| Dec 31, 2023 | 5.91 Mn |
| Sep 30, 2023 | -1.23 Mn |
| Jun 30, 2023 | -2.89 Mn |
| Mar 31, 2023 | 1.81 Mn |
| Dec 31, 2022 | 575,000.00 |
| Sep 30, 2022 | 1.12 Mn |